oxaliplatin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Colonic Neoplasms
Conditions
Colonic Neoplasms
Trial Timeline
Aug 1, 2004 → —
NCT ID
NCT00263055About oxaliplatin
oxaliplatin is a approved stage product being developed by Sanofi for Colonic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00263055. Target conditions include Colonic Neoplasms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00238849 | Phase 2 | UNKNOWN |
| NCT00846482 | Pre-clinical | Completed |
| NCT00261092 | Phase 2 | Completed |
| NCT00129870 | Approved | Terminated |
| NCT00256308 | Phase 2 | Terminated |
| NCT00263055 | Approved | Completed |
| NCT00280618 | Phase 2 | Completed |
| NCT00263354 | Phase 2 | Completed |
| NCT01042691 | Phase 1 | Completed |
| NCT00174564 | Phase 2 | Completed |
| NCT00259363 | Phase 1/2 | Terminated |
| NCT00403624 | Phase 1/2 | Completed |
Competing Products
6 competing products in Colonic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzastaurin HCl | Eli Lilly | Phase 2 | 52 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Indium labeled IMP-205xm734 | Gilead Sciences | Phase 1 | 32 |
| psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) | Pfizer | Pre-clinical | 22 |
| Methylnaltrexone Bromide (MNTX) + Placebo | Pfizer | Approved | 84 |
| Oxaliplatin (SR96669) | Sanofi | Phase 3 | 76 |